| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2013-09-11 | ATIR™ | patients with high-risk malignancies | 1-2 | Kiadis Pharma (The Netherlands) | Cancer - Oncology |
| 2013-09-10 | daratumumab | multiple myeloma |
2 | Janssen Biotech - J&J (USA) Genmab (Denmark) | Cancer - Oncology |
| 2013-09-10 | cadazolid | Clostridium difficile associated diarrhea | 3 | Actelion (Switzerland) | Infectious diseases |
| 2013-09-10 | Opsumit® (macitentan) | pulmonary arterial hypertension (PAH) | 3 | Actelion (Switzerland) | Rare diseases - Cardiovascular diseases - Autoimmune diseases |
| 2013-09-10 | cabozantinib | advanced hepatocellular carcinoma | 3 | Exelixis (USA - CA) | Cancer - Oncology |
| 2013-09-09 | CYT003 | allergic asthma |
2a | Cytos Biotechnology (Switzerland) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2013-09-06 | PRO053 (exon 53 specific phosphorothioate oligonucleotide) | Duchenne muscular dystrophy (DMD) |
1-2 | Prosensa (The Netherlands) | Genetic diseases - Neuromuscular diseases - Rare diseases |
| 2013-09-05 | MAGE-A3 antigen-specific cancer immunotherapeutic | melanoma | 3 | GSK (UK) | Cancer - Oncology |
| 2013-09-04 | dipraglurant | dystonia, primary generalized torsion dystonia 1 (DYT1) | preclinical studies | Addex Therapeutics (Switzerland) | Neuromuscular diseases - Rare diseases - CNS diseases - Neurological diseases |
| 2013-09-04 | Envarsus® (LCP-Tacro™) | prevention of graft rejection in kidney transplantation | 3 | Veloxis Pharmaceuticals (Denmark) | Transplantation |
| 2013-09-04 | olaparib | BRCA mutated ovarian cancer | 3 | AstraZeneca (UK) | Cancer - Oncology |
| 2013-09-04 | True Human™ antibody therapy for methicillin resistant staphylococcus aureus (MRSA) | methicillin resistant staphylococcus aureus (MRSA) infections | preclinical | XBiotech (USA - TX) | Infectious diseases |
| 2013-09-03 | ATX-MS-1467 | multiple sclerosis | 1 | Apitope (Belgium - UK) Merck Serono, a Merck KGaA company (Germany) | Autoimmune diseases - Neurodegenerative diseases |
| 2013-09-03 | MVA85A-IMX313 | tuberculosis | 1 | Imaxio (France) | Infectious diseases |
| 2013-09-03 | ELND005 | Down Syndrome | 2a | Elan (Ireland) | Genetic diseases |
| 2013-09-03 | JX-594/TG6006 (Pexa-Vec -pexastimogene devacirepvec) | hepatocellular carcinoma | 2b | Transgene (France) Jennerex (USA) | Cancer Oncology |
| 2013-08-30 | Nuvigil® (armodafinil) | major depression associated with bipolar 1 disorder | 3 | Teva Pharmaceutical Industries (Israel) | Mental diseases - CNS diseases |
| 2013-08-27 | Seprehvir® (HSV1716) | malignant pleural mesothelioma | 1-2a | Virttu Biologics (UK) | Cancer - Oncology |
| 2013-08-27 | Akvano®/calcipotriol spray formulation | psoriasis | 1-2 | Lipidor (Sweden) | Autoimmune diseases – Dermatological diseases |
| 2013-08-27 | lampalizumab | dry age-related macular degeneration | 2 | Roche (Switzerland) | Ophtalmological diseases |
